C9093Outpatient PPS
Injection, ranibizumab, via sustained release intravitreal implant (susvimo),
Short description: Inj., susvimo, 0.1 mg
- Effective date
- July 1, 2022
- Termination date
- —
Related codes (C-series)
C1052Hemostatic agent, gi, topicC1062Intravertebral fx aug implC1300Hyperbaric oxygenC1600Cath, bladed, vasc prepC1601Endo, single, pulmonaryC1602Orth/matrx/bn fill drug-elutC1603Ret dev, laser, ivc filterC1604Grft, trnsmurl/trnsvens bypsC1605Pmkr, dual, leadlessC1606Adapter, us to endoscopeC1607Neurostim integ rechgC1608Prosthesis, dual mob cmc1
Frequently asked questions
What is HCPCS code C9093?
C9093 is a HCPCS Level II code for Injection, ranibizumab, via sustained release intravitreal implant (susvimo),.
What category is HCPCS code C9093 in?
C9093 falls under the Outpatient PPS category of HCPCS Level II.
When did HCPCS code C9093 become effective?
C9093 has been effective since July 1, 2022, per CMS's quarterly HCPCS update.
HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.